Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

FGEN

FibroGen Inc

Mar 21 • 04:00PM ET

0.3150

Dollar change -0.0215
Percentage change -6.39	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN REGN ALNY IONS NBIX MDGL EXEL ARGX PRTA

| Held by: VTI VXF VHT IWC BTEC FESM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	6.59%	Shs Outstand	100.92M	Perf Week	-28.30%
Market Cap	31.79M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	0.00%	Shs Float	94.26M	Perf Month	-59.22%
Income	-47.58M	PEG	-	EPS next Q	0.03	Inst Own	36.10%	Short Float	5.62%	Perf Quarter	-9.51%
Sales	156.01M	P/S	0.20	EPS this Y	-23.96%	Inst Trans	-24.76%	Short Ratio	1.46	Perf Half Y	-25.00%
Book/sh	-2.42	P/B	-	EPS next Y	-30.25%	ROA	-23.27%	Short Interest	5.30M	Perf Year	-86.60%
Cash/sh	0.50	P/C	0.63	EPS next 5Y	-6.51%	ROE	-	52W Range	0.18 - 2.80	Perf YTD	-40.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.75%	ROI	-	52W High	-88.75%	Beta	0.84
Dividend TTM	-	Quick Ratio	1.45	Sales past 5Y	-29.24%	Gross Margin	82.03%	52W Low	75.00%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.47	EPS Y/Y TTM	83.59%	Oper. Margin	-29.77%	RSI (14)	36.79	Volatility	13.31% 14.91%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	5.59%	Profit Margin	-30.50%	Recom	2.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	131.23%	Payout	-	Rel Volume	0.64	Prev Close	0.34
Sales Surprise	-87.41%	EPS Surprise	228.57%	Sales Q/Q	-88.44%	Earnings	Mar 17 AMC	Avg Volume	3.63M	Price	0.31
SMA20	-22.90%	SMA50	-35.47%	SMA200	-42.33%	Trades		Volume	2,329,349	Change	-6.39%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

Mar-18-25 08:26AM	Q4 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -21.80%
03:02AM	FibroGen Inc (FGEN) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines with ... (GuruFocus.com)
Mar-17-25 04:28PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 04:45PM	FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.78% -5.33%
04:02PM	Loading…
Feb-20-25 04:02PM	FibroGen sells China unit to AstraZeneca for $160m (Pharmaceutical Technology) +37.44% -8.61%
06:40AM	AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal (Reuters)
06:30AM	FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million (GlobeNewswire)
05:55AM	AstraZeneca deepens China presence with FibroGen deal (BioPharma Dive)
Dec-16-24 08:05AM	FibroGen Appoints David DeLucia as Chief Financial Officer (GlobeNewswire)
Nov-13-24 10:22AM	Q3 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -14.07%
02:21AM	FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions (GuruFocus.com)
Nov-12-24 06:10PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +14.18%
05:06PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Third Quarter 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Nov-04-24 04:05PM	FibroGen to Report Third Quarter 2024 Financial Results (GlobeNewswire) -5.65%
Oct-09-24 05:09PM	FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts (GuruFocus.com)
Sep-16-24 01:32AM	Duchenne muscular dystrophy: major trials and events to watch in 2023 (Clinical Trials Arena)
Sep-03-24 04:05PM	FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.19% +20.36%
Aug-06-24 06:15PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:10PM	FibroGen: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 11:54AM	FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials (Pharmaceutical Technology) -47.56%
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
Jul-30-24 04:07PM	FibroGen to Report Second Quarter 2024 Financial Results (GlobeNewswire) -8.04%
04:05PM	FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update (GlobeNewswire)
Jun-18-24 08:00AM	FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 (GlobeNewswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-03-24 04:05PM	FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire)
04:02PM	Loading…
04:02PM	FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors (GlobeNewswire)
09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:00AM	FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-23-24 05:05PM	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adib Deyaa	Chief Medical Officer	Jun 12 '24	Buy	1.17	22,123	25,884	82,123	Jun 13 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

FGEN

FibroGen Inc

Upgrade your FINVIZ experience